- United States
- /
- Healthcare Services
- /
- NasdaqGS:CRVL
Returns on Capital Paint A Bright Future For CorVel (NASDAQ:CRVL)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed. Ultimately, this demonstrates that it's a business that is reinvesting profits at increasing rates of return. And in light of that, the trends we're seeing at CorVel's (NASDAQ:CRVL) look very promising so lets take a look.
What Is Return On Capital Employed (ROCE)?
Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. To calculate this metric for CorVel, this is the formula:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
0.35 = US$121m ÷ (US$546m - US$204m) (Based on the trailing twelve months to March 2025).
Therefore, CorVel has an ROCE of 35%. In absolute terms that's a great return and it's even better than the Healthcare industry average of 10%.
View our latest analysis for CorVel
While the past is not representative of the future, it can be helpful to know how a company has performed historically, which is why we have this chart above. If you want to delve into the historical earnings , check out these free graphs detailing revenue and cash flow performance of CorVel.
So How Is CorVel's ROCE Trending?
We like the trends that we're seeing from CorVel. The numbers show that in the last five years, the returns generated on capital employed have grown considerably to 35%. The company is effectively making more money per dollar of capital used, and it's worth noting that the amount of capital has increased too, by 21%. The increasing returns on a growing amount of capital is common amongst multi-baggers and that's why we're impressed.
What We Can Learn From CorVel's ROCE
A company that is growing its returns on capital and can consistently reinvest in itself is a highly sought after trait, and that's what CorVel has. And with the stock having performed exceptionally well over the last five years, these patterns are being accounted for by investors. So given the stock has proven it has promising trends, it's worth researching the company further to see if these trends are likely to persist.
If you'd like to know about the risks facing CorVel, we've discovered 1 warning sign that you should be aware of.
If you'd like to see other companies earning high returns, check out our free list of companies earning high returns with solid balance sheets here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:CRVL
CorVel
Provides workers’ compensation, general and auto liability, and hospital bill auditing and payment integrity solutions.
Flawless balance sheet with solid track record.
Similar Companies
Market Insights
Weekly Picks

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets
Onto Innovation: The Advanced Packaging Chokepoint 51.3% undervalued intrinsic discount

Investment Analysis (May 2026)
Recently Updated Narratives
Lumentum: An AI-Fueled Recovery That Has Not Yet Earned Its $74 Billion Tag
The Hidden Southeast Asian Compounder: How an Overlooked Storage and Leasing Company Quietly Created Wealth for a Decade

Warren Buffett Just Bet $10 Billion on Google. The Catch? You May Already Be Too Late.
Popular Narratives
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026
